The approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or B without ...
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...
Snubbed by Tesla, Mexico's new president pledged Friday to create a Mexican-made small, affordable electric car to compete ...
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
The Food and Drug Administration approved Pfizer's Hympavzi to prevent or reduce bleeding episodes in patients with certain kinds of hemophilia, the pharmaceutical company said. Write to Rob Curran at ...
Recent health developments include HIV infections from organ transplants in Brazil, Sanofi's potential sale of a stake in its ...
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...
The Food and Drug Administration approved Pfizer's Hympavzi to prevent or reduce bleeding episodes in patients with certain kinds of hemophilia A and B. "Pfizer's Hympavzi Approved for Treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback